TORONTO, ONTARIO -- (Marketwired) -- 07/30/14 -- Mr. Ian Ihnatowycz, announced that effective today, he has entered into an amending agreement (the "Amending Agreement") to the US$25 million convertible note (the "Note") of Trimel Pharmaceuticals Corporation (the "Issuer") issued on July 16, 2014 to his private investment holding company First Generation Capital Inc. (the "Offeror").
Pursuant to the Amending Agreement, the maximum number of common shares issuable on conversion of the Note has been reduced from 37,746,796 to 8,945,796. The remaining terms of the Note are unchanged. If the maximum amount of the Note that may be converted was converted in accordance with its terms, the Offeror would hold a total of 47,602,093 common shares of the Issuer, corresponding to a securityholding percentage of approximately 23.70% (based on a total of 200,873,234 common shares outstanding following any such conversion, as advised by the Issuer).
The Note was acquired for investment purposes. Depending upon the circumstances, Mr. Ihnatowycz may, from time to time, acquire additional securities or related financial instruments of the Issuer or dispose of all or a portion of the securities or related financial instruments of the Issuer previously acquired.
Additional information is provided in the early warning report filed on www.sedar.com.
For further information or a copy of the early warning report please contact:
First Generation Capital Inc. 40 King Street West, Suite 3515 Toronto, ON M5H 3Y2 Attention: Ian Ihnatowycz, President and CEO Telephone: (416) 304-9910
Contacts:
First Generation Capital Inc.
Ian Ihnatowycz
President and CEO
(416) 304-9910
